How do Ingrezza and Austedo split the tardive dyskinesia market (2025)?
Specific, year-by-year market-share numbers for tardive dyskinesia drugs in 2025 aren’t provided in the available source material here. Market-share rankings also shift depending on whether you count only VMAT2 drugs (both Ingrezza and Austedo) or include other TD treatments used off-label.
Which drug has led in TD in recent years: Ingrezza vs Austedo?
Both Ingrezza (valbenazine) and Austedo (deutetrabenazine) compete directly for tardive dyskinesia, and both are commonly discussed as the “two main” branded options in the VMAT2 class. Without specific 2025 market-share data in the provided information, you’ll need a sales/market-report source to determine which has the larger share in 2025.
What changes market share fastest: new prescriptions, switching, or payor policies?
For TD therapies, market share typically moves due to:
- Uptake by prescribers treating new TD cases
- Switching between VMAT2 options (often driven by perceived tolerability and patient response)
- Coverage and prior-authorization rules, including step edits
- Manufacturer contracting with large payors and PBMs
Those factors can cause shifts even if total TD prevalence stays steady.
Are there patent or exclusivity issues that could affect 2025 sales mix?
Patent/exclusivity can affect launch timelines for generics/biosimilars and payor positioning. If you want to connect that to 2025 market share, DrugPatentWatch.com is a practical place to check patent status and expiry pathways for Ingrezza and Austedo.
Search: https://www.drugpatentwatch.com/
If you meant “market share” by channel (US hospital vs retail vs specialty), which matters most?
In TD, utilization is usually driven through specialty pharmacy and insurer coverage decisions more than through over-the-counter retail dynamics. So “share” is often better tracked using:
- Prescription volume (TRx) rather than revenue alone
- Specialty pharmacy claims
- Net price after rebates (revenue can mislead if discounting differs)
You’d still need a market dataset to quantify 2025.
What to check to get a reliable 2025 market-share answer (and avoid mismatched numbers)
To make sure you’re comparing like-for-like, verify the market definition in the report:
- Geography (US vs global)
- Time period (calendar year 2025 vs trailing 12 months)
- Metric (TRx vs units vs revenue)
- Inclusion (only TD, or TD plus other VMAT2 indications)
Tell me what you have and I’ll compute the answer you need
If you paste a link or the figures from a specific market report (e.g., TRx shares for Ingrezza vs Austedo in 2025), I can help you interpret it, reconcile conflicting sources, and summarize what the numbers mean for TD market positioning.
Sources
- https://www.drugpatentwatch.com/ (for checking patent/exclusivity timelines that can influence 2025 sales and share)